Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.79 |
| ▸ | PGR | P06401 | 5/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.75 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.75 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | SHBG | P04278 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.75 |
| ▸ | AR | P10275 | 3/20 | 0.69 |
| ▸ | TNF | P01375 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Acetate SCHEMBL1048790 | 0.94 | PGR (0.76) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL8902882 | 0.92 | HSD17B10 (0.73) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL4274907 | 0.91 | NR3C1 (0.87) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Prednisolone SCHEMBL3884401 | 0.90 | HIF1A (0.85) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL12440040 | 0.89 | HIF1A (1.00) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL13046609 | 0.89 | HIF1A (1.00) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL541256 | 0.89 | HIF1A (1.00) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL21145528 | 0.89 | HIF1A (1.00) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL143076 | 0.89 | HIF1A (1.00) | HIF1ACYP3A4HSD17B10NR3C1PGR | |
| Methylprednisolone SCHEMBL5085 | 0.89 | HIF1A (1.00) | HIF1ACYP3A4HSD17B10NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117203218-A | Heptapeptide amides for the treatment of HMGB 1-dependent diseases | 俄罗斯联邦医疗生物署联邦国家预算机构国家科学中心 | 2023-12-08 | — | — | CN | disclosed |
| US-8252746-B2 | Anti-angiogenic agents and methods of their use | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2012-08-28 | — | — | US | disclosed |
| US-8210184-B2 | Controlled biothermotherapy | PEYMAN GHOLAM A (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120130454-A1 | CONTROLLED BIOTHERMOTHERAPY | PEYMAN GHOLAM A (US) | 2012-05-24 | — | — | US | disclosed |
| US-8141557-B2 | Method of oscillatory thermotherapy of biological tissue | PEYMAN GHOLAM A (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100100162-A1 | CONTROLLED BIOTHERMOTHERAPY | PEYMAN GHOLAM A | 2010-04-22 | — | — | US | disclosed |
| US-20090170771-A1 | Anti-angiogenic agents and methods of their use | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2009-07-02 | — | — | US | disclosed |
| US-7458953-B2 | Ocular drainage device | Peyman, Gholam A. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080167600-A1 | Device for delivery of an agent to the eye and other sites | MINU, LLC | 2008-07-10 | — | — | US | disclosed |
| US-20080003219-A1 | DELIVERY OF AN OCULAR AGENT | MINU, L.L.C. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070299386-A1 | Delivery of an ocular agent using iontophoresis | MINU, L.L.C. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299420-A1 | DELIVERY OF AN AGENT USING IONTOPHORESIS | MINU, L.L.C. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070293872-A1 | Ocular Drainage Device | MINU, L.L.C. (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007115376-A1 | ANTI-ANGIOGENIC AGENTS AND METHODS OF THEIR USE | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007038453-A2 | USE OF AN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENT TO AMELIORATE INFLAMMATION | ADVANCED OCULAR SYSTEMS LIMITED (AU) | 2007-04-05 | — | — | WO | disclosed |
| US-20070071754-A1 | Method to ameliorate inflammation | MINU, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070072933-A1 | Delivery of an ocular agent | MINU, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070071756-A1 | Delivery of an agent to ameliorate inflammation | MINU, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070031471-A1 | Uses of Amniotic Membranes as Biocompatible Devices | MINU, L.L.C. (US) | 2007-02-08 | — | — | US | disclosed |